BACKGROUND: Several prospective studies suggest that use of cholesterol-lowering statin drugs is inversely associated with advanced stage and possibly high-grade prostate cancer. One study reported that men with low cholesterol had a lower risk of high-grade prostate cancer. Given these findings, we investigated the association between low serum cholesterol and prostate cancer risk in the Prostate Cancer Prevention Trial. METHODS: We conducted a cohort study of 5,586 men ages >or=55 years who were randomized to theplaceboarm of the Prostate Cancer Prevention Trial between 1993 and 1996. Serum cholesterol was measured enzymatically at entry. By the end of follow-up, 1,251 prostate cancer cases were confirmed. We used logistic regression to calculate the multivariable odds ratio (OR) of total, and Gleason 2 to 6 (n = 993), 7 (n = 199), and 8 to 10 (n = 59) prostate cancer comparing low serum (normal, <200 mg/dL) to high-serum (borderline and elevated cholesterol, >or=200 mg/dL) cholesterol. RESULTS: Men with low cholesterol had a lower risk of Gleason 8 to 10 prostate cancer [OR, 0.41; 95% confidence interval (CI), 0.22-0.77] than men with high cholesterol. No association was present for prostate cancer overall (OR, 0.97; 95% CI, 0.85-1.11), Gleason 2 to 6 disease (OR, 1.03; 95% CI, 0.89-1.18), or Gleason 7 disease (OR, 0.93; 95% CI, 0.69-1.24). CONCLUSION: These prospective results support that men with low cholesterol have a reduced risk of high-grade prostate cancer. These and other contemporary data that suggest that cholesterol metabolism should be investigated further in the etiology of prostate cancer.
RCT Entities:
BACKGROUND: Several prospective studies suggest that use of cholesterol-lowering statin drugs is inversely associated with advanced stage and possibly high-grade prostate cancer. One study reported that men with low cholesterol had a lower risk of high-grade prostate cancer. Given these findings, we investigated the association between low serum cholesterol and prostate cancer risk in the Prostate Cancer Prevention Trial. METHODS: We conducted a cohort study of 5,586 men ages >or=55 years who were randomized to the placebo arm of the Prostate Cancer Prevention Trial between 1993 and 1996. Serum cholesterol was measured enzymatically at entry. By the end of follow-up, 1,251 prostate cancer cases were confirmed. We used logistic regression to calculate the multivariable odds ratio (OR) of total, and Gleason 2 to 6 (n = 993), 7 (n = 199), and 8 to 10 (n = 59) prostate cancer comparing low serum (normal, <200 mg/dL) to high-serum (borderline and elevated cholesterol, >or=200 mg/dL) cholesterol. RESULTS:Men with low cholesterol had a lower risk of Gleason 8 to 10 prostate cancer [OR, 0.41; 95% confidence interval (CI), 0.22-0.77] than men with high cholesterol. No association was present for prostate cancer overall (OR, 0.97; 95% CI, 0.85-1.11), Gleason 2 to 6 disease (OR, 1.03; 95% CI, 0.89-1.18), or Gleason 7 disease (OR, 0.93; 95% CI, 0.69-1.24). CONCLUSION: These prospective results support that men with low cholesterol have a reduced risk of high-grade prostate cancer. These and other contemporary data that suggest that cholesterol metabolism should be investigated further in the etiology of prostate cancer.
Authors: L Wuermli; M Joerger; S Henz; H-P Schmid; W F Riesen; G Thomas; W Krek; T Cerny; S Gillessen Journal: Prostate Cancer Prostatic Dis Date: 2005 Impact factor: 5.554
Authors: Ian M Thompson; Chen Chi; Donna Pauler Ankerst; Phyllis J Goodman; Catherine M Tangen; Scott M Lippman; M Scott Lucia; Howard L Parnes; Charles A Coltman Journal: J Natl Cancer Inst Date: 2006-08-16 Impact factor: 13.506
Authors: D L Morris; N O Borhani; E Fitzsimons; R J Hardy; C M Hawkins; J F Kraus; D R Labarthe; L Mastbaum; G H Payne Journal: Cancer Date: 1983-11-01 Impact factor: 6.860
Authors: Ian M Thompson; Catherine M Tangen; Phyllis J Goodman; M Scott Lucia; Howard L Parnes; Scott M Lippman; Charles A Coltman Journal: J Urol Date: 2007-05 Impact factor: 7.450
Authors: H Tulinius; N Sigfússon; H Sigvaldason; K Bjarnadóttir; L Tryggvadóttir Journal: Cancer Epidemiol Biomarkers Prev Date: 1997-11 Impact factor: 4.254
Authors: E Dawn Flick; Laurel A Habel; K Arnold Chan; Stephen K Van Den Eeden; Virginia P Quinn; Reina Haque; Endel J Orav; John D Seeger; Marianne C Sadler; Charles P Quesenberry; Barbara Sternfeld; Steven J Jacobsen; Rachel A Whitmer; Bette J Caan Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-10-30 Impact factor: 4.254
Authors: Wildon R Farwell; Leonard W D'Avolio; Richard E Scranton; Elizabeth V Lawler; J Michael Gaziano Journal: J Natl Cancer Inst Date: 2011-04-15 Impact factor: 13.506
Authors: Byron H Lee; Margaret G Taylor; Peggy Robinet; Jonathan D Smith; Jessica Schweitzer; Ephraim Sehayek; Sara M Falzarano; Cristina Magi-Galluzzi; Eric A Klein; Angela H Ting Journal: Cancer Res Date: 2012-12-11 Impact factor: 12.701
Authors: Emma H Allott; Lauren E Howard; Matthew R Cooperberg; Christopher J Kane; William J Aronson; Martha K Terris; Christopher L Amling; Stephen J Freedland Journal: BJU Int Date: 2014-05-08 Impact factor: 5.588
Authors: Katharine N Sourbeer; Lauren E Howard; Gerald L Andriole; Daniel M Moreira; Ramiro Castro-Santamaria; Stephen J Freedland; Adriana C Vidal Journal: BJU Int Date: 2014-10-20 Impact factor: 5.588
Authors: Elin Thysell; Izabella Surowiec; Emma Hörnberg; Sead Crnalic; Anders Widmark; Annika I Johansson; Pär Stattin; Anders Bergh; Thomas Moritz; Henrik Antti; Pernilla Wikström Journal: PLoS One Date: 2010-12-03 Impact factor: 3.240